Popular terms

Indole topics
Indole Derivatives
Tryptophan
Pharmaceutically Acceptable Salt
Protease Inhibitors
Antivirals
Antiinfective
Pharmaceutical Formulations
Protease Inhibitor
Pharmaceutical Formulation
Immunomodulator
Entry Inhibitors
Piperazine
Cycloalkyl
Alkyl Group
Carbon Atoms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Indole patents



      

This page is updated frequently with new Indole-related patent applications.




Date/App# patent app List of recent Indole-related patents
07/21/16
20160206595 
 Indole-3-aldehyde for treating dysreactive immune disorders patent thumbnailIndole-3-aldehyde for treating dysreactive immune disorders
The therapeutic use of bacteria, specifically but not only lactobacilli, which produce indole-3-aldehyde, or directly of indole-3-aldehyde itself, is proposed as a means of prevention and treatment of immune dysreactive disorders in which the hyper-inflammatory or autoimmune component represents the basic element. .
Universita' Degli Studi Di Perugia


07/14/16
20160200709 
 Indole compound as inhibitor of necrosis patent thumbnailIndole compound as inhibitor of necrosis
The present invention relates to an indole compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.. .
Lg Life Sciences Ltd.


07/14/16
20160200674 
 Ido inhibitors patent thumbnailIdo inhibitors
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


07/07/16
20160194331 
 Method for producing spirooxindole derivative patent thumbnailMethod for producing spirooxindole derivative
The present invention is intended to provide a method for efficiently producing and providing a compound having a spirooxindole skeleton, for example, a compound having a spirooxindole skeleton and having antitumor activity that inhibits the interaction between mdm2 protein and p53 protein, or an intermediate thereof, using an asymmetric catalyst. A compound having an optically active tricyclic dispiroindole skeleton is efficiently obtained through a catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a lewis acid..
Daiichi Sankyo Company, Limited


07/07/16
20160194313 
 Indole amide compound as inhibitor of necrosis patent thumbnailIndole amide compound as inhibitor of necrosis
The present invention relates to an indole amide compound represented by formula (1), a pharmaceutically acceptable salt or isomer thereof, a composition for prevention or treatment of necrosis and necrosis-associated diseases, and a method for preparing the composition, the composition comprising the indole compound or the pharmaceutically acceptable salt or isomer thereof as an active ingredient.. .
Lg Life Sciences Ltd.


06/30/16
20160185771 
 Conjugate of benzofuranone and indole or azaindole, and preparation and uses thereof patent thumbnailConjugate of benzofuranone and indole or azaindole, and preparation and uses thereof
The present invention relates to an oxo indirubin or isoindigo derivative, an oxo aza indirubin or isoindigo derivative, and their optical isomers, racemes, cis/trans isomers and pharmaceutically acceptable salts, which can be used for preparing a drug for treating or preventing diseases such as glucose metabolic disorder, inflammatory or autoimmune disease, neurodegenerative disease, a mental illness, tissue proliferation disease or tumors.. .

06/30/16
20160185757 
 Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof patent thumbnailIndole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
Agents of formulas (i)/(ii)/(iii) for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.. .

06/30/16
20160185721 
 Indole-carboxamides patent thumbnailIndole-carboxamides
The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.. .

06/23/16
20160175289 
 Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof patent thumbnailTetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
And stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula i compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..

06/16/16
20160168210 
 Derivatives of collagen-binding hairpin peptides patent thumbnailDerivatives of collagen-binding hairpin peptides
Compounds of interest, for example active pharmaceutical ingredients, probes or inactive carriers, may be delivered to a site of interest by conjugating the compound of interest to a collagen-binding linear hairpin (cblh) peptide to form a molecule of formula (i) and then providing the molecule to the site of interest where the cblh peptide binds to collagen at the site of interest thereby delivering the compound of interest to the site of interest. Molecule of formula (i) are: (i) where: y is a first compound of interest; z is a second compound of interest; n and m are independently 0 or 1 with the proviso that at least one of n and m is 1; and, cblh is a collagen-binding linear hairpin peptide having 19 or fewer amino acids and having a turn amino acid sequence comprising 4 to 6 amino acid residues providing a stable turn structure, the turn sequence flanked on one side by a first flanking sequence having a wt(w/y) motif and flanked on the other side by a rr second flanking sequence having a wt(w/r) motif, the w residue at position 1 of the first flanking sequence forming a cross-strand indole-indole or cation-π interaction pair with the amino acid residue at position 3 of the second flanking sequence without any disulfide bond..
National Research Council Of Canada


06/16/16
20160168147 

Isotopically enriched azaindoles


The present invention relates to deuterated compounds that are useful for inhibiting janus kinases and processes and intermediates useful for preparing such compounds.. .
Vertex Pharmaceuticals Incorporated


06/16/16
20160168135 


The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.. .
Abbvie Deutschland Gmbh & Co. Kg


06/16/16
20160168091 

Enantiomeric separation and purification of 2,3,4,9-tetrahydro-1h-carbazole-4-carboxylic acid amide derivatives


A method for the purification of cyclic indole compounds that provides advantages over previously-known methods. Using the method of the present invention allows for the facile preparation of a good quality solid form of these compounds..
Ge Healthcare Limited


06/16/16
20160168090 

Novel indole derivatives and their use in neurodegenerative diseases


The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of p2x7, and for the treatment of p2x7-related disorders.. .
Merck Patent Gmbh


06/09/16
20160159798 

(1-azinone)-substituted pyridoindoles


Wherein r1 is h or optionally substituted alkyl; r2, r3, r4 are each independently selected from h, —o-alkyl, —s-alkyl, alkyl, halo, —cf3, and —cn; g is —cr12r13—nr5— or —nr5—cr12r13; r5 is h, optionally substituted alkyl, optionally substituted heterocycle, —c(═o)—r6, —c(═o)—o—r7, or —c(═o)—nr19r20; r6 and r7 are each optionally substituted alkyl or optionally substituted heterocycle; r8, r9, r10, r11, r12, r13, r19 and r20 are each independently selected from h or optionally substituted alkyl; r14 and r15 are each independently h or halogen; l is —ch2—o—, —ch2ch2—, —ch═ch— or a bond; and b is aryl or heteroaryl or cycloalkyl; with the proviso that, when l is a direct bond, b cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.. .

06/09/16
20160159794 

Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection


Wherein r1, r2, r3, r4, r5, w and x are as described herein, compositions including the compounds and methods of using the compounds.. .

06/09/16
20160159787 

Cis-tetrahydro-spiro(cyclohexane-1, 1' -pyrido[3,4-b]indole)-4-amine compounds


Cis-tetrahydro-spiro(cyclohexane-1,1′-pyrido[3,4-b]indole)-4-amine compounds which act on the nociceptin/orl-1 receptor system as well as on the μ-opioid receptor system and which are distinguished in particular by selective effectiveness in the treatment of chronic pain, such as inflammatory pain, visceral pain, tumour pain, and neuropathic pain, without at the same time developing pronounced effectiveness against acute, nociceptive pain.. .
Gruenenthal Gmbh


06/09/16
20160159740 

Indole-3-carbinol derivatives


The present invention relates to novel stable indole-3-carbinol derivatives of formula-i and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with inflammation..
Cadila Pharmaceuticals Limited


06/02/16
20160155946 

Conjugated polymers


The invention relates to novel conjugated polymers containing one or more [1,2,5]thiadiazolo[3,4-e]isoindole-5,7-dione (tid) repeating units, to methods for their preparation and educts or intermediates used therein, to polymer blends, mixtures and formulations containing them, to the use of the polymers, polymer blends, mixtures and formulations as organic semiconductors in, or for the preparation of, organic electronic (oe) devices, especially organic photovoltaic (opv) devices and organic photodetectors (opd), and to oe, opv and opd devices comprising, or being prepared from, these polymers, polymer blends, mixtures or formulations.. .
Merck Patent Gmbh


06/02/16
20160152615 

Prodrugs of substituted azaindoleoxoacetic piperazine derivatives


This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives.
Bristol-myers Squibb Company


06/02/16
20160152605 

Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof


The present invention provides a compound of formula i: (i) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of factor b. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition..
Novartis Ag


06/02/16
20160152599 

Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them


Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .

05/26/16
20160145258 

Inhibitor crystalline form and preparation method and use thereof


The present invention relates to a new crystalline forms of the inhibitor, 5-fluoro-3-phenyl-2-[(s)-1-(9h-purin-6-ylamino)-propyl]-3h-quinazoline-4-one; the new crystalline form, compared to known forms, has one or more improved properties. The present invention also relates to a method for preparing a new crystalline form of 5-fluoro-3-phenyl-2-[(s)-1-(9h-purin-6-ylamino)-propyl]-3h-quinazolin-4-one, a pharmaceutical composition thereof and a use thereof in preparation of a pharmaceutical for the treatment and/or prevention of diseases such as chronic lymphocytic leukemia and indolent non-hodgkin's lymphoma..
Hangzhou Pushai Pharmaceutical Technology Co., Ltd.


05/26/16
20160143870 

Ido inhibitors


There are disclosed compounds of formula (i) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


05/19/16
20160137653 

Immunoregulatory agents


Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided..
Flexus Biosciences, Inc.


05/19/16
20160137652 

Immunoregulatory agents


Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided..
Flexus Biosciences, Inc.


05/19/16
20160137601 

Method for providing stable isoindole derivatives


Method for producing an isoindole derivative, the isoindole derivative obtainable by the methods, a methods for stabilizing an isoindole derivative, and methods for detection and/or quantification of macromolecules.. .
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v


05/19/16
20160137595 

Ido inhibitors


There are disclosed compounds of formula (i) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


05/12/16
20160130269 

7-azaindole derivatives


Compounds of the formula (i) in which r, r1, r2 and r3 have the meanings indicated in claim 1, are inhibitors of pdk1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.. .
Merck Patent Gmbh


05/12/16
20160130226 

Spiro-substituted oxindole derivatives having ampk activity


The present invention relates to compounds of formula (i), which have valuable pharmacological properties, in particular are activators of ampk and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2..
Boehringer Ingelheim International Gmbh


05/12/16
20160128979 

Modified release formulation


Drug products in the form of modified release formulations comprising the drug substance (-)-(3ar,4s,7ar)-4-hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (afq056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with parkinson's disease and exhibiting l-dopa induced dyskinesia..

05/05/16
20160126468 

Indenoindole derivative and organic electroluminescent element


According to the present invention, there are provided an indenoindole derivative represented by the following general formula (1); and an organic electroluminescent element including a pair of electrodes and at least one organic layer sandwiched therebetween, wherein the above compound is used as a constituent material for the at least one organic layer. The indenoindole derivative of the present invention provides an organic compound, which is excellent in hole injection/transport performance, has electron blocking capability, is highly stable in a thin film state, and excels in heat resistance, as a material for a high efficiency, high durability organic electroluminescent element.
Hodogaya Chemical Co., Ltd.


05/05/16
20160120976 

Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma


The present invention concerns methods of treating relapsed/resistant non-hodgkin's lymphoma using combination therapy with an anti-cd20 antibody or fragment and an anti-cd74 antibody or fragment. In preferred embodiments, the antibody combination is administered along with at least one other therapeutic agent.
Immunomedics, Inc.


04/28/16
20160115162 

Radiosynthesis of tau radiopharmaceuticals


This disclosure relates to a one-step method for preparing the tau radiopharmaceutical, [18f]t807, using an unprotected or protected precursor (e.g., tertbutyl 7-(6-nitropyridin-3-yl)-sh-pyrido[4,3-b]indole-5-carboxylate). An improved one-step synthesis method to prepare [18f]t807 was achieved with a protected (e.g., t-boc) precursor, offering increased solubility, a faster synthesis as well as simpler purification and automation.
The General Hospital Corporation


04/28/16
20160115156 

Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof


This invention relates to certain metabolites of n-(1-methyl-5-(trifluoromethyl)-1h-pyrazol-3-yl)-5-((6-((methyl-amino)methyl)pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide in particular, the present invention relates to pharmaceutical compositions comprising these metabolites, as well as processes for their preparation and their use in the treatment of diseases.. .
Novartis Ag


04/28/16
20160115126 

Indole carboxamide compounds


Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

04/21/16
20160107991 

Processes and intermediates for preparing indole pharmaceuticals


The invention described herein pertains to processes and intermediates for preparing indole containing pharmaceuticals, particularly to processes and intermediates for preparing selective estrogen receptor modulators, such as bazedoxifene.. .

04/21/16
20160106869 

Fluorescent solid lipid nanoparticles composition and preparation thereof


The present invention discloses a solid lipid nanoparticle (sln) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula i and/or ii: d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal.

04/21/16
20160106731 

Tricyclic indole mcl-1 inhibitors and uses thereof


The present invention provides for compounds that inhibit the activity of an anti-apoptotic bcl-2 family member myeloid cell leukemia-1 (mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of mcl-1 protein..

04/21/16
20160106711 

3-3-di-substituted-oxindoles as inhibitors of translation initiation


Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described..

04/14/16
20160102077 

Indole-3-carboxamides as kinase inhibitors


Or a pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4, r5, r6, r7, r8, r9 and x are as defined herein. The compounds of formula i are useful as receptor tyrosine kinase (rtk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases..

04/14/16
20160102054 

Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)


Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of src homology 2-domain containing protein tyrosine phosphatase-2..

04/14/16
20160101083 

Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles


The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing diindolylmethane-related indoles. Additive and synergistic interaction of diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections.

04/07/16
20160098514 

Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample


A programmed computer functioning as a classifier operates on mass spectral data obtained from a blood-based patient sample to predict indolence or aggressiveness of prostate cancer. Methods of generating the classifier and conducting a test on a blood-based sample from a prostate cancer patient using the classifier are described..
Biodesix, Inc.


04/07/16
20160096828 

Indole-1-carboxamides as kinase inhibitors


Or a pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4, r5, r6, r7, and x are as defined herein. The compounds of formula i are useful as receptor tyrosine kinase (rtk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases..

03/31/16
20160091494 

Diagnostic hepatic cancer


Methods and kits for analysing a sample from a test subject. The methods involve determining the level of at least one compound selected from the group consisting of n-acetylglutamate, methionine, acetylcarnitine, indole-3-acetate, 2-oxoglutarate, anserine, aspartate and butyrate in the sample from the test subject; and comparing the level of the at least one compound determined to at least one control level, wherein the levels of the at least one compound are indicative of whether the subject has hepatic cancer..
Imperial Innovations Ltd


03/31/16
20160089368 

Treatment of mastocytosis with masitinib


The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.. .
Ab Science


03/24/16
20160084779 

Nuclear magnetic resonance implemented synthetic indole and indazole cannabinoid detection, identification, and quantification


The present invention provides a method for detecting synthetic indole and indazole cannabinoids in a sample known or suspected to contain a synthetic indole or indazole cannabinoid. A deuterated solvent is added to the solid sample, creating a suspension.
Hofstra University


03/24/16
20160083363 

Substituted indoles as selective protease activated receptor 4 (par-4) antagonists


Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition..
Vanderbilt University


03/17/16
20160075711 

Compounds for the inhibition of indoleamine-2,3-dioxygenase


The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of ido, and for the treatment of ido-related disorders.. .
Merck Patent Gmbh


03/17/16
20160075709 

Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments


Wherein the variables take the various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in pain therapy.. .

03/17/16
20160075703 

Substituted azaindoleoxoacetic piperazine derivatives


These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or hiv entry inhibitors. More particularly, the present invention relates to the treatment of hiv and aids..

03/10/16
20160068809 

Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants


The invention relates to the use of 1-(β-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of indoleamine 2,3-dioxygenase (ido) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.. .
Idogen Ab


03/10/16
20160068531 

Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection


Wherein r1, r2, r3, r4, r5, r6, w1, w2, w3, a and x are as described herein, compositions including the compounds and methods of using the compounds.. .

03/03/16
20160060268 

Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments


Wherein the variables take the various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in pain therapy.. .

03/03/16
20160060266 

Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization


Presently provided are inhibitors of ido and tdo and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.. .
Newlink Genetics Corporation


03/03/16
20160060237 

Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (i)..
Bristol-myers Squibb Company


03/03/16
20160058770 

Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas


—use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of non-hodgkin's lymphoma (nhl), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-hodgkin's lymphoma (nhl), in particular follicular lymphoma (fl), chronic lymphocytic leukaemia (cll), marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), transformed lymphoma (tl), or peripheral t-cell lymphoma (ptcl); —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-hodgkin's lymphoma (nhl), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-hodgkin's lymphoma (nhl), in particular follicular lymphoma (fl), chronic lymphocytic leukaemia (cll), marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), mantle cell lymphoma (mcl), transformed lymphoma (tl), or peripheral t-cell lymphoma (ptcl); —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of the expression of pi3k isoforms, btk and ikk, bcr activation, bcr downstream activation of nfkb pathway, c-myc, ezh2, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and —a method of determining the level of a component of one or more of the expression of pi3k isoforms, btk and ikk, bcr activation, bcr downstream activation of nfkb pathway, c-myc, ezh2.. .
Bayer Pharma Aktiengesellschaft


02/25/16
20160052938 

Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors


Wherein the groups r1 to r7, a, v, w, x, y, n, r and q are as defined herein, their use as inhibitors of mdm2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.. .

02/25/16
20160051600 

Gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for treating chronic renal disease


The invention relates to the fields of application of health, biotechnology and nutrition, the aim of the invention being to provide a gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease, the characteristics and components thereof reducing the concentration of uremic toxins, improving the renal function of the patient with an increase in urea, creatinine, uric acid, p-cresols or indoles in the blood. The gelatinous mixture of probiotics and prebiotics with synergic symbiotic action for the treatment of chronic renal disease is easier to administrate orally as it does not require the consumption of liquids for the administration thereof, reducing liquid retention.
Nutrimentos Inteligentes, S.a. De C.v.


02/18/16
20160046648 

4-phenylpiperidines, their preparation and use


The present invention provides a compound having the structure: (structurally represented) wherein r1, r2, r3, r4, and r5 are each independently h, halogen, cf3 or c1-c4 alkyl; r6 is h, oh, or halogen; b is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.. .
The Trustees Of Columbia University In The City Of New York


02/18/16
20160046596 

Inhibitors of the kynurenine pathway


The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
Curadev Pharma Private Ltd.




Indole topics: Indole Derivatives, Tryptophan, Pharmaceutically Acceptable Salt, Protease Inhibitors, Antivirals, Antiinfective, Pharmaceutical Formulations, Protease Inhibitor, Pharmaceutical Formulation, Immunomodulator, Entry Inhibitors, Piperazine, Cycloalkyl, Alkyl Group, Carbon Atoms

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Indole for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Indole with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.8979

4490

3 - 0 - 102